Flamel Technologies S.A. (ADR)  

(Public, NASDAQ:FLML)   Watch this stock  
Find more results for flml
12.79
0.00 (0.00%)
Jul 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 7.56 - 25.97
Open     -
Vol / Avg. 0.00/199,562.00
Mkt cap 530.80M
P/E 114.60
Div/yield     -
EPS 0.11
Shares 41.24M
Beta 1.41
Inst. own 75%
Aug 10, 2016
Flamel Technologies SA Extraordinary Shareholders Meeting - 7:00AM EDT - Add to calendar
Aug 10, 2016
Flamel Technologies SA Annual Shareholders Meeting - 7:00AM EDT - Add to calendar
Aug 8, 2016
Half Year 2016 Flamel Technologies SA Earnings Call - 10:00AM EDT - Add to calendar
Aug 8, 2016
Half Year 2016 Flamel Technologies SA Earnings Release - 9:30AM EDT - Add to calendar
Jul 15, 2016
Flamel Technologies SA Annual Shareholders Meeting (Estimated)
Jun 21, 2016
Flamel Technologies SA at JMP Securities Life Sciences Conference
Jun 7, 2016
Flamel Technologies SA at Jefferies Healthcare Conference
May 10, 2016
Flamel Technologies SA at Bank of America Merrill Lynch Health Care Conference
May 9, 2016
Q1 2016 Flamel Technologies SA Earnings Call - Webcast
May 9, 2016
Q1 2016 Flamel Technologies SA Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -17.61% 23.47%
Operating margin 15.30% 41.25%
EBITD margin - 66.70%
Return on average assets -10.88% 20.89%
Return on average equity -37.18% 87.66%
Employees 109 -
CDP Score - -

Address

33 avenue du Dr. Georges Levy Parc Club Du Moulin A Vent
VENISSIEUX, 69200
France
+33-4-72783434 (Phone)
+33-4-72783435 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel's drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd.

Officers and directors

Stephen H. Willard Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Michael S. Anderson Chief Executive Officer, Director
Bio & Compensation  - Reuters
Michael F. Kanan Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Rafael Jorda Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Sandra Hatten Senior Vice President - Quality and Regulatory Affairs
Bio & Compensation  - Reuters
Steven A. Lisi Senior Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregory J. Davis Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregg Stetsko Ph.D. Vice President - Research & Development
Age: 56
Bio & Compensation  - Reuters
Catherine Castan Director - Micropump Platform (Oral Drugs) and Intellectual Property
Bio & Compensation  - Reuters
Christian Kalita Pharmacist and Director - Quality Assurance and Regulatory Affairs
Bio & Compensation  - Reuters